| Alexza Pharmaceuticals Pipeline | ||||
| Product Candidate | Drug Compound | Target Indication | Development Status | |
| AZ-001 | Prochlorperazine | Migraine headaches | Phase IIb enrolled | |
| AZ-002 | Alprazolam | Acute panic attacks | Phase IIa ongoing | |
| AZ-003 | Fentanyl | Acute pain | Phase I completed | |
| AZ-004 | Loxapine | Acute agitation in schizophrenia | Phase IIa enrolled | |
| Product Description: | ||||
| AZ-001: (Staccato prochlorperazine).
We are developing AZ-001 to treat patients suffering
from acute migraine headaches. To date, we have
completed a 50 subject Phase I study and a 75 patient
Phase IIa study. A 400 patient Phase IIb
study was initiated in June 2006. This Phase
IIb study was designed as an outpatient, multi-center,
randomized, double-blind, single-dose, placebo-controlled
study. Patient enrollment was completed in
December 2006, and initial results are expected
to be reported by the end of Q1 2007. Read Press Release |
||||
| AZ-002:
(Staccato alprazolam).We are developing
AZ-002 for the acute treatment of panic attacks
associated with panic disorder. There are currently
no drugs approved to acutely treat associated
panic attacks. To date, we have completed a 50
subject Phase I study. A Phase IIa proof-of-concept
clinical trial in patients with panic disorder
is ongoing. Read Press Release |
||||
| AZ-003: (Staccato fentanyl).
We are developing AZ-003 for the treatment of patients
with acute pain, including patients with breakthrough
cancer pain and postoperative patients with acute
pain episodes. Enrollment of a 50 subject Phase
I clinical trial was completed, and initial results
were announced in December 2006.
Read Press Release |
||||
| AZ-004:
(Staccato loxapine). We are developing
AZ-004 for the treatment of acute agitation in
patients with schizophrenia. To date, we have
complete a 50 subject Phase I study. A
120 patient Phase IIa proof-of-concept study
was initiated in September 2006. This Phase
IIa study was designed as a multi-center, randomized,
double-blind, placebo-controlled study in an
in-patient clinical setting. Patient enrollment
was completed in January 2007 and initial results
are expected to be reported by the end of Q1 2007.
Read Press Release |
||||